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Purpose: The aim of the present study was to investigate the association of glutathione S-transferase GSTT1 and
GSTM1 genotypes with pseudoexfoliative glaucoma (PEXG) in a group of Pakistani patients.
Methods: Multiplex polymerase chain reaction was used to study the GSTT1 and GSTM1 polymorphisms in 165 PEXG
patients and 162 unaffected controls.
Results: In the current study we describe a significant gender-specific association of GSTT1 and GSTM1 null genotypes
with PEXG. The three null genotype combinations (i.e., T1M0, T0M1, and T0M0) were found at significantly higher
frequencies in the PEXG patients as compared to the controls (χ2=21.82, p<0.001). This association was specifically
related to the female patients (χ2=35.63, p<0.001); no such association was seen in the male patients (χ2=2.28, p>0.05).
Conclusions: The results suggest that there is a significant involvement of the GSTT1 and GSTM1 polymorphisms in
female Pakistani patients having PEXG, which suggests a possible gender-specific impairment of detoxification in this
group.
Xenobiotic compounds of exogenous and endogenous
origin are a substantial threat to the human cells as they lead
to the production of highly reactive oxygen species (ROS).
The cells produce numerous antioxidants that counter the
effects of these compounds by reducing their accumulation.
Glutathione (GSH) is an important antioxidant that protects
against cellular damage caused by environmental toxins as
well  as  from  ROS-mediated  injury.  GSH  works  by
neutralizing ROS and xenobiotics with the help of glutathione
S-transferase (GST); this enzyme catalyzes the conjugation of
these compounds with GSH, which being water soluble can
thus be easily eliminated from the body [1-3].
Mammalian GSTs are made up of a supergene family of
catalytic  and  binding  proteins  located  on  at  least  seven
different genes, which are divided into three major classes:
cytosolic,  mitochondrial  and  microsomal  GSTs.  Tissue
expression studies have shown that most of the cytosolic GSTs
are expressed in the kidneys and the liver, where they play an
important role in the detoxification of various endogenous and
exogenous toxic chemicals in the body [4-6].
Of the cytosolic GSTs, the Mu (µ), Theta (σ), and Pi (π)
genes have been found at different frequencies in various
ethnic groups. In the Mu class of GSTs the M1 null genotype
(M0)  is  common  in  the  Chinese,  Japanese,  French,  and
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English, with a frequency between 43% and 58% [7-11]. In
the Theta class of GSTs the T1 null genotype (T0) has been
found at varying frequencies in different ethnic groups: 64.4%
in Chinese, 60.2% in Koreans, and 20%–24% in African-
Americans [12]. Biochemical studies have associated these
allelic variations to intra-individual differences in the ability
to metabolize environmental and cellular toxins [13].
It  has  been  shown  that  individuals  carrying  the  null
genotypes of GST may have higher levels of intermediates of
oxidative metabolism because the detoxification pathways
have  been  disrupted,  and  this  then  directly  or  indirectly
exacerbates the pathological effects of ROS.
This has important implications in a range of diseases; for
example, various types of cancers, asthma and others, and has
also demonstrated involvement in causing neuronal cell death
in  neurodegenerative  diseases,  such  as  Alzheimer,  motor
neuron disease and Parkinson [14-17]. GSTs have also been
reported to be widely expressed in different ocular tissues.
Thus, for individuals carrying the null genotypes, the body’s
defense  against  oxidative  damage  may  be  impaired,
contributing  to  manifestation  of  the  ocular  diseases  in
question [18-23].
Polymorphisms of GST have previously been shown to
be associated with glaucoma, cataract, exudative age-related
macular degeneration as well as various spontaneous optic
neuropathies [13,24-27].
Several  studies  have  been  conducted  in  different
populations  to  determine  the  association  of  GSTT1  and
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[13,26,28], but to date only three studies have been reported
on pseudo-exfoliative glaucoma (PEXG) in populations of
Arabs, Turks and Swedes [29-31]. There was no significant
association found between PEXG and the null genotypes of
GSTT1 and GSTM1 in the Turks and Swedes, whereas in the
Arab glaucoma patients (n=107), in a study that included
POAG, PCAG and PEXG, a significant association of all the
deletion  genotypes  was  observed  [29].  However,  after
stratification of patients by glaucoma type the T0M0 genotype
was not found to be significantly associated with any type of
glaucoma.
The aim of the present study was to determine if there
was  a  significant  association  of  the  GSTT1  and  GSTM1
polymorphisms with PEXG in a Pakistani cohort. The study
was  approved  by  the  Departmental  Ethics  Committee  of
COMSATS Institute of Information Technology, Islamabad
and the relevant Hospitals’ Ethics Committee and conformed
to the principles of the Declaration of Helsinki. Informed
written consent was taken from all patients and unaffected
control  individuals  before  sampling.  PEXG  patients  were
recruited from the out-patients Department of the Al-Shifa
Trust Eye Hospital, Rawalpindi and Christian Eye Hospital,
Taxila.
METHODS
Criteria for patient selection, sample collection and DNA
extraction:  Complete  ophthalmic  examinations  were
performed on the PEXG patients, including measurement of
cup-to-disk  ratio,  tonometeric  assessment  of  intra-ocular
pressure and slit lamp biomicroscopy was performed to detect
any presence of exfoliative material along the papillary border
and on the iris. Following this, the pupils of the patients were
dilated and the anterior of the lens surface was examined for
any deposits of white material. Angles were measured in all
the patients with the help of gonioscopy. All of the healthy
control individuals were also examined and they were found
to have normal visual fields, no exfoliation material in the eye
or any other evidence of glaucoma. Blood samples from all
the  patients  and  controls  were  collected  by  venipuncture;
genomic  DNA  was  extracted  by  a  conventional  phenol
chloroform method, as described previously [32].
Genotype analysis of GSTT1 and GSTM1 polymorphisms: To
determine the GSTT1 and GSTM1 genotypes of the subjects,
multiplex polymerase chain reaction (PCR) amplification was
performed  using  the  following  primers:  GSTT1  forward
primer  5′-TTC  CTT  ACT  GGT  CCT  CAC  ATC  TC-3′;
GSTT1 reverse primer 5′-TCA CCG GAT CAT GGC CAG
CA-3′;  GSTM1  forward  primer  5′-GAA  CTC  CCT  GAA
AAG CTA AAG C-3′; and GSTM1 reverse primer 5′-GTT
GGG CTC AAA TAT ACG GTG G-3′. Beta globin gene
sequence amplification was used as an internal control in the
PCR reactions, for which the primers were: forward primer
5′-CAA CTT CAT CCA CGT TCA CC-3′; reverse primer 5′-
GAA GAG CCA AGG ACA GGT AC-3′. Each 25 μl PCR
reaction contained 1× Taq Buffer (10 mM Tris-HCl, pH 9.0,
50 mM KCl, 0.1% Triton X-100, 0.01% gelatine; Fermentas,
Burlington,  Ontario),  30  pmol  of  each  primer,  1.5  mM
MgCl2,  0.3  mM  dNTP,  1.5  U  of  Taq  DNA  polymerase
(Fermentas) and 100 ng of genomic DNA.
Amplification was performed with initial denaturation at
95 °C for 5 min, followed by 30 cycles at 95 °C for 1 min,
65 °C for 1 min and 72 °C for 1 min, with a final extension at
72  °C  for  7  min.  PCR  products  were  electrophoretically
separated on 2% agarose gels and the bands were visualized
by UV transillumination. For the T1M1 genotype three bands
were obtained: a 459 bp band of GSTT1, a 209 bp band of
GSTM1 and a 268 bp band of the internal control (β-globin
gene; Figure 1). The T1M0 genotype produced two bands of
459 bp and 268 bp; the T0M1 genotype produced two bands
of 209 bp and 268 bp. In the case of the T0M0 null genotype
only, the β-globin gene internal control band (268 bp) was
observed. To confirm the null results, confirmatory PCR tests
were  performed  separately  for  the  GSTT1  as  well  as  the
GSTM1 genotypes, using β-globin gene amplification as the
internal control, under identical conditions as those described
above,  but  using  only  the  GSTT1  and  β-globin  or  the
GSTM1 and β-globin primers, respectively.
Statistical  analysis:  Statistical  analysis  of  the  genotype
frequencies  of  both  the  PEXG  patients  and  controls  was
performed using the chi-square test (χ2). To prevent any false
positive inference, Bonferroni correction (p′b) was applied to
the  genotype  data.  Correction  involved  multiplying  the  p
value obtained after each single test with the total number of
independent tests (k) performed during the study [33,34]. The
Sidak correction (p′s), an approximation of Bonferroni, was
also  applied  to  correct  the  p  value  as  some  Bonferroni
corrected values were >1 [35,36]. Note that for the Bonferroni
corrected values, the level of significance remained 0.05; i.e.,
the association of any genotype group/variable with k×p<0.05
was considered as statistically significant [33]. The formulae
for the calculation of the Bonferroni and Sidak values are as
follows:
p′b = k × p
p′s = 1 − (1 − p)k
where k is the number of genotype groups tested and p is the
raw value obtained from the χ2 test.
All analyses were performed using SPSS v.16 statistical
analysis  software  (SPSS  Inc.,  Chicago,  IL)  and  StatCalc
EpiInfo package v.6 (Atlanta, GA).
RESULTS
The  case-controlled  study  included  165  patients  with
glaucoma (53% males, mean age 45.8±10.1 years and 47%
Molecular Vision 2010; 16:2146-2152 <http://www.molvis.org/molvis/v16/a230> © 2010 Molecular Vision
2147females,  mean  age  46.31±11.6  years),  as  well  as  162
unaffected controls (52% males, mean age 43.8±13.9 years
and 48% females, mean age 43.1±10.9 years); there was no
statistically significant difference (p>0.05) in the mean age of
male/female patients and controls.
There  was  a  significant  difference  in  the  overall
distribution of the GSTT1 and GSTM1 genotypes in the PEXG
patients  and  controls  (χ2=21.82,  p<0.001;  Table  1).  The
difference between individual genotypes remained significant
even after the application of Bonferroni and Sidak corrections
(p’b & p’s<0.05). When the subjects were stratified according
to  gender  the  overall  genotype  distribution  of  the  female
patients was found to be significantly associated with the
disease  (χ2=35.63,  p<0.001;  Table  1);  this  remained
significant  even  after  applying  the  Bonferroni  correction
(p’b & p’s<0.001). Interestingly, the T0M0 null genotype was
exclusively present in the PEXG female patients (χ2=20.12, p,
p’b & p’s<0.001). In the male patients 8.2% of the controls had
the T0M0 null genotype as compared to 6% of the PEXG male
patients (χ2=0.11, p, p’b & p’s>0.05, OR=0.81 [95% CI=0.20–
3.24]; Table 1).
The gender distribution of the null genotypes GSTT0 and
GSTM0 were also compared between patients and contols;
these  genotypes  were  found  at  a  significantly  higher
frequency in the female patients than in the female controls
(χ2=19.90,  and  χ2=18.7,  respectively,  p<0.05;  Table  2);
whereas in males the frequency of the null genotypes did not
differ  significantly  between  the  groups  (χ2=0.43,  χ2=0.01,
respectively, p>0.05). However, the male control samples as
compared to the female controls had a significantly higher
frequency of both the null genotypes GSTT0 and GSTM0
(χ2=12.13, χ2=14.41, respectively, p<0.001; Table 3), whereas
in patients in both these groups these genotypes were not
statistically  different  from  each  other  (χ2=0.44,  χ2=0.53,
respectively, p>0.05).
DISCUSSION
Oxidative stress along with cellular senescence is one of the
major factors affecting cellular processes. The inability of the
cells to cope with oxidative stress is due to a breakdown of
the body’s antioxidant defenses due to excessive production
of  ROS;  this  in  turn  leads  to  damage  to  the  cellular
macromolecules,  including  DNA,  proteins  and  lipids.  To
counteract the stress-induced damage, the cells upregulate
antioxidant enzymes, such as GST [37].
In  the  eye  a  system  of  trabecular  meshwork  (TM)
regulates the outflow of aqueous humor, and maintains normal
intraocular pressure (IOP); therefore, any challenge to the
structural  and  functional  integrity  of  TM  results  in  the
development of glaucoma. Several lines of evidence suggest
that one effect of the generation of oxidative free radicals in
the glaucomatous eye is the progressive loss of TM [38]. In
an experimental rat model of glaucoma the retinal ganglion
cells (RGC) and glial cells showed extensive protein and lipid
oxidation, which appears to lead to apoptosis of these and
other  neuronal  cells  [37,39].  Thus,  to  maintain  the
homeostatic balance between the production of ROS and their
clearance, the eye, under stress, is required to produce higher
levels  of  antioxidants.  Indeed,  the  glaucomatous  eye
upregulates  several  stress-related  genes,  including  GST,
which are involved in the detoxification of ROS and other
related compounds [39,40].
Although, under stress, GST and other antioxidants are
demonstrably  upregulated,  the  glaucomatous  eye  fails  to
prevent oxidative damage, a fact that points to an underlying
molecular or genetic defect. One such genetic risk factor is the
presence  of  the  GST  null  genotype  in  patients  having
oxidative, stress-related diseases.
A potent antioxidant 8-hydroxy-2′-deoxyguanosine (8-
OH-dG) has been shown to be present at 3.6 fold higher levels
in the TM of POAG patients, as compared to controls [41]. In
these  patients  there  was  a  positive  correlation  between
Figure 1. Multiplex PCR amplification
product  of  the  GSTT1,  GSTM1  and
internal  control  β-globin  genes.  The
amplified  products  were  separated  by
electrophoresis on 2% agarose gel. Lane
L, 100bp DNA ladder; lane 1, 4, 9, and
10, T1/M0 genotype (459 bp and 268 bp
fragments);  lane  2,  3,  and  8,  T1/M1
genotype (459 bp, 268 bp, and 209 bp
fragments);  lane  5,  T0/M1  genotype
(268 bp and 209 bp fragments); lane 6,
7,  and  11,  T0/M0  genotype  (268  bp
fragments).
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2149oxidative DNA damage and intraocular pressure as well as
visual field defects. The GSTT1 null genotype was found to
be more common in POAG cases, who also showed 2.2 fold
higher levels of 8-OH-dG as compared to the other genotypes
[41,42], resulting in oxidative DNA damage in the TM of
these patients. A higher level of oxidative damage to the
trabecular meshwork has also been seen in POAG patients
with  the  GSTM1  null  genotype,  indicating  the  possible
involvement  of  these  genotypes  in  the  manifestation  of
disease [42].
In primary cultures of human optic nerve head astrocytes
from glaucomatous eyes it has been observed that the basal
levels of GSH antioxidants were well below those of primary
cultures from normal astrocytes; these data combined with all
the  other  evidence  indicates  that  oxidative  stress  plays  a
significant  role  in  the  manifestation  and  progression  of
glaucoma [40].
Recently, using cDNA arrays, the involvement of several
stress-related  candidate  genes  was  studied  in  PEXG.  The
authors found that a large set of cytoprotective gene products,
including antioxidant defense enzymes (e.g., GST) and stress-
inducible  transcription  factors,  were  consistently  down-
regulated in PEXG at both the mRNA and protein levels; this
finding supports the conjecture that GSTs play an important
role in protecting the eye against the development of PEXG
[41].
The  present  study  was  based  on  the  hypothesis  that
inadequate expression of GST in PEXG correlates with the
null genotypes. This hypothesis has been tested in Swedes
[31] and Turks [28], but in those populations no significant
contribution of the polymorphic variants of GSTs with PEXG
was found. To the best of our knowledge, the investigators in
all of those studies did not stratify their data according to
gender. This may be significant considering our knowledge
that in mice there is a higher expression of some types of GSTs
in females as compared to males [6]. This indicates that any
defects in the relevant genetic pathways in females could
exacerbate the risk of disease to a significantly higher level
than for males.
The importance of the present study is that an association
between PEXG and all the GST null genotype combinations
was  observed  and  this  remained  significant  even  after
Bonferroni correction. In addition, after stratifying the data
according to gender, a clear association of the null genotypes
with only the female PEXG patients was found; this occurred
because a large number of female PEXG patients were found
to  carry  the  null  genotypes,  in  different  combinations,  as
compared to the female controls (Table 1).
The GSTT1 and GSTM1 null genotypes in the total data
set of the patient cohort was also compared, as well as in the
data  stratified  according  to  gender.  Although  an  overall
statistically  significant  difference  in  the  null  genotype
distribution between patients and controls was observed, this
was due to the significantly higher distribution of the null
genotypes  in  the  female  patients,  as  compared  to  female
controls (Table 2). In addition it must be pointed out that the
TABLE 2. COMPARISON OF GSTT1 AND GSTM1 NULL GENOTYPES ACCORDING TO GENDER DISTRIBUTION IN PATIENTS AND CONTROLS. A P<0.05 WAS
CONSIDERED STATISTICALLY SIGNIFICANT.
Genotype Group Controls (n=162) Patients (n=165) p (χ2)
T0 Total 16 (10%) 39 (24%) <0.05 (11.06)
T1   146 (90%) 126 (76%)  
M0 Total 58 (36%) 85 (52%) <0.05 (8.20)
M1   104 (64%) 80 (48%)  
Genotype   Controls (n=77) Patients (n=77) p (χ2)
T0 Females 1 (1%) 20 (26%) <0.05 (19.90)
T1   76 (99%) 57 (74%)  
M0 Females 16(21%) 42(55%) <0.05 (18.70)
M1   61(79%) 35(45%)  
Genotype   Controls (n=85) Patients (n=88) p (χ2)
T0 Males 15(18%) 19(22%) >0.05(0.43)
T1   70(82%) 69(78%)  
M0 Males 42(49%) 43(49%) >0.05(0.01)
M1   43(51%) 45(51%)  
TABLE 3. COMPARISON OF GSTT1 AND GSTM1 NULL GENOTYPES BETWEEN MALE AND FEMALE CONTROLS AND PATIENTS. A P<0.05 WAS CONSIDERED
STATISTICALLY SIGNIFICANT.
  Controls   Patients  
Genotypes (Males) (n=85) (Females) (n=77) p (χ2) (Males) (n=88) (Females) (n=77) p (χ2)
GSTT1 null 15 (18%) 1 (1%) <0.001 (12.13) 19 (22%) 20 (26%) >0.05 (0.44)
GSTM1 null 42 (49%) 16 (21%) <0.001 (14.41) 43 (49%) 42 (55%) >0.05 (0.53)
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2150significantly higher frequency of the T1 and M1 in the female
unaffected controls as compared to the males (Table 3) could
be  a  result  of  a  gender-specific  protective  effect  of  these
genotypes in the females only.
The association of the GSTM1 null genotype with female
PEXG patients in the current study is in accordance with the
data  of  a  group  of  Greek  patients  with  multiple  sclerosis
[42]; using this data we calculated and compared the gender-
wise  distribution  of  the  null  genotypes  of  GSTT1  and
GSTM1 between the Greek controls and patients. We found
that the female patients had a significantly higher frequency
of the GSTM1 null genotype (65.5% versus 41.7% in controls;
χ2=4.91, p=0.02) while in males there was no difference in the
distribution of any of the null genotypes.
Another interesting aspect of the present study is that, in
addition to the GSTM1 null genotype, the frequency of the
GSTT1 null genotype in the female PEXG patients occurred
also at a significantly higher level than in the control females
(Table  2),  while  in  the  Greeks  there  was  no  significant
difference in this group (χ2=0.05, p=0.82). Also, in contrast to
our data, in the Greeks the T0M0 combined null genotype was
not found to be associated with the females, which points to
the possible association of the GST T0M0 genotype with
PEXG only in the Pakistani female patients; the resultant
vulnerability to cellular and oxidative stress conditions may
therefore be a contributing factor in the disease pathology that
possibly has ethnic as well as gender associations.
In conclusion, we would like to emphasize the importance
of  conducting  further  studies  in  different  populations  to
further ascertain the association of GST with PEXG; this will
allow  the  development  of  a  consensus  regarding  the
involvement of GST in glaucoma. There is also a need to better
understand  the  mechanisms  associated  with  the  null
genotypes in female patients.
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